All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GC007g
Therapeutic Area: Oncology Product Name: GC007g
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
The seamless Phase 1/2 pivotal clinical trial of GC007g will enable Gracell to potentially substantially accelerate the clinical development of GC007g in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): GC012F
Therapeutic Area: Oncology Product Name: GC012F
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Jefferies
Deal Size: $100.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 18, 2020
Details:
Gracell's lead FasTCAR-enabled candidate, GC012F, has achieved multiple minimal residual disease, negative stringent complete responses in relapsed or refractory multiple myeloma patients in an ongoing investigator-initiated Phase 1 trial in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eftilagimod Alpha,Paclitaxel
Therapeutic Area: Oncology Product Name: IMP321
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Immutep
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2020
Details:
EOC Pharma trial will be a randomised, double-blind, placebo controlled phase II clinical study to evaluate its lead product candidate eftilagimod alpha in combination with paclitaxel in HER2-/HR+ metastatic breast cancer patients who have progression after endocrine therapy.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lemzoparlimab
Therapeutic Area: Oncology Product Name: TJC4
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 13, 2020
Details:
The purpose of the call is to provide an expanded analysis of the clinical efficacy signal from the U.S. phase 1 clinical trial of Lemzoparlimab (also known as TJC4), which is not previously discussed.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Letaplimab,Rituximab
Therapeutic Area: Oncology Product Name: IBI188
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2020
Details:
The phase 1a clinical study is evaluating the tolerability, safety, and PK/PD properties of IBI188 (letaplimab) as monotherapy for advanced malignancies that failed in standard treatments. With a total of over 60 subjects enrolled, letaplimab was well tolerated generally.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CTA101
Therapeutic Area: Oncology Product Name: CTA101
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 10, 2020
Details:
The data will be presented regarding the pre-clinical development, manufacturing, and IIT clinical results of the company’s lead product, CTA101, a CRISPR-Cas9-engineered off-the-shelf CD19/CD22 dual-targeted CAR T cell product, in R/R B-cell acute Lymphoblastic Leukemia.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Lemzoparlimab,Pembrolizumab,Rituximab
Therapeutic Area: Oncology Product Name: TJC4
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Lemzoparlimab was well tolerated up to 30 mg/kg on a weekly basis without priming dosing strategy. No dose-limiting toxicity and no clinical or laboratory evidence of hemolytic anemia were observed throughout.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): CT053
Therapeutic Area: Oncology Product Name: CT053
Highest Development Status: Phase I Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Loyal Valley Capital
Deal Size: $186.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing November 03, 2020
Details:
Series C funding will help CARsgen accelerate its ongoing clinical programs and achieve market approval of its leading assets, improving the standard of care in cancers with tremendous unmet medical need.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
